Advertisement

Adverse Effects and Pharmacovigilance

  • Avinash Arivazhahan
  • Sushil Kiran Kunder
Chapter

Abstract

No drug can be testified to be entirely free of undesired effects. These undesired or unintended effects of drug administration are broadly called adverse effects. When the concept of causality is factored in, the term adverse drug reaction is used. This causality assessment can be done in several ways, Naranjo scale and WHO-UMC scale being the most common ones. Pharmacovigilance is a growing domain that concerns the detection, assessment, understanding and prevention of drug-related adverse effects. On a similar line, hemovigilance is the set of activities that govern adverse effects related to transfusion chains. When the medical materials and devices are involved, it is called materiovigilance, and when cosmetic products are concerned, the cosmetovigilance comes in to play. Addictovigilance is an ill-defined category of events that cover drugs of addictive or recreational misuse. This chapter covers the broad types of vigilance (medicovigilance) and their relevance in the Indian scenario.

Keywords

Pharmacovigilance Adverse effects Hemovigilance Materiovigilance Cosmetovigilance Addictovigilance 

Bibliography

  1. Boparai JK, Singh S (2015) Hemovigilance: a new beginning in India. Int J App Basic Med Res 5:200–202CrossRefGoogle Scholar
  2. Faber JC (2004) Haemovigilance procedure in transfusion medicine. Hematol J 5:S74–S82CrossRefGoogle Scholar
  3. Flesland O, Wiersum-Osselton JC (2016) Donor vigilance and hemovigilance. In: Tl S, McCullough J, Snyder EI, Solheim B, Strauss RJ (eds) Rossi’s principles of transfusion medicine. Wiley Blackwell, Chichester, pp 58–68CrossRefGoogle Scholar
  4. Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J (2018) Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network? Fund Clin Pharmacol 32:643–651CrossRefGoogle Scholar
  5. Gupta P, Janodia MD, Jagadish PC, Udupa N (2010) Medical device vigilance systems: India, US, UK, and Australia. Med Devices (Auckl) 3:67–79Google Scholar
  6. Jain A, Kaur R (2012) Hemovigilance and blood safety. Asian J Transfus Sci 6(2):137–138CrossRefGoogle Scholar
  7. Jouanjus E, Gibaja V, Kahn J-P, Haramburu F, Daveluy A (2015) Signal identification in addictovigilance: the functioning of the French system. Therapie 70:113–131CrossRefGoogle Scholar
  8. Kalaiselvan V, Thota P, Singh GN (2016) Pharmacovigilance programme of India: recent developments and future perspectives. Indian J Pharmacol 48:624–628CrossRefGoogle Scholar
  9. Kalaiselvan V, Srivastava S, Singh A, Gupta SK (2018) Pharmacovigilance in India: present scenario and future challenges. Drug Saf 42:339–346CrossRefGoogle Scholar
  10. Medical device adverse event reporting form. [Online] [cited 2018 Sep 20]; Available from: URL http://ipc.nic.in/writereaddata/mainlinkFile/File528.pdf
  11. Moretti U, Velo G (2008) Cosmetovigilance: the “beautiful” risk. Drug Saf 31:437–439CrossRefGoogle Scholar
  12. Mukherjee S, Maiti R (2016) Haemovigilance: a current update in Indian perspective. J Clin Diagn Res 10:5–9Google Scholar
  13. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239–245CrossRefGoogle Scholar
  14. Pharmacovigilance Programme of India (PvPI). [Internet] 2017 [cited 2018 Oct 13]. Available from: http://www.ipc.gov.in/PvPI/about.html
  15. Rani S, Singh K (2018) Materiovigilance: an emerging discipline. Int J Sci Res 7:15–16Google Scholar
  16. Sarma P, Kumar H, Medhi B (2017) Cosmetovigilance in India: need of the day. Indian J Pharmacol 49(5):341–343PubMedPubMedCentralGoogle Scholar
  17. Tripathi KD (2013) Adverse drug effects. In: Essentials of medical pharmacology, 7th edn. Jaypee Publishers, New Delhi, pp 82–91Google Scholar
  18. Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC et al (2015) Sudden death in patients with cardiac implantable electronic devices. JAMA Intern Med 175:1342–1350CrossRefGoogle Scholar
  19. Udupa N, Ligade V (2016) Need of cosmetovigilance in India. Value Health 19(7):A836CrossRefGoogle Scholar
  20. Vigan M, Castelain F (2014) Cosmetovigilance: definition, regulation and use “in practice”. Eur J Dermatol 24(6):643–649PubMedGoogle Scholar
  21. Zaki SA (2011) Adverse drug reaction and causality assessment scales. Lung India 28(2):152–153CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Avinash Arivazhahan
    • 1
  • Sushil Kiran Kunder
    • 2
  1. 1.Sanofi India Ltd.ChennaiIndia
  2. 2.Sanofi India Ltd.HyderabadIndia

Personalised recommendations